Principal Financial Group Inc. Has $45.53 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Principal Financial Group Inc. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 679,167 shares of the medical device company's stock after selling 95,415 shares during the period. Principal Financial Group Inc. owned 0.17% of DexCom worth $45,531,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AlphaCentric Advisors LLC bought a new position in shares of DexCom in the third quarter valued at $280,000. Quintet Private Bank Europe S.A. increased its holdings in shares of DexCom by 324.1% in the third quarter. Quintet Private Bank Europe S.A. now owns 4,105 shares of the medical device company's stock valued at $275,000 after buying an additional 3,137 shares in the last quarter. QRG Capital Management Inc. increased its holdings in shares of DexCom by 8.6% in the third quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company's stock valued at $1,052,000 after buying an additional 1,248 shares in the last quarter. Asset Management One Co. Ltd. increased its holdings in shares of DexCom by 10.4% in the third quarter. Asset Management One Co. Ltd. now owns 235,474 shares of the medical device company's stock valued at $15,786,000 after buying an additional 22,268 shares in the last quarter. Finally, National Pension Service increased its holdings in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company's stock valued at $63,671,000 after buying an additional 37,363 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 426 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. BTIG Research lowered their price target on shares of DexCom from $156.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, July 26th. Royal Bank of Canada lowered their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Robert W. Baird boosted their price target on shares of DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, August 5th. Finally, Sanford C. Bernstein boosted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Trading Up 0.5 %

NASDAQ DXCM traded up $0.35 during trading hours on Monday, hitting $70.31. The company's stock had a trading volume of 4,531,853 shares, compared to its average volume of 3,910,189. The stock has a fifty day moving average of $69.66 and a 200 day moving average of $93.10. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $27.46 billion, a P/E ratio of 42.54, a PEG ratio of 2.15 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.